Roche Registration Gmbh
SpainAll drugs from this manufacturer
-
It is used to treat adults with a type of lung cancer called 'non-small cell lung cancer' (NSCLC) that is 'ALK positive'. It may be prescribed after surgery to prevent the cancer from returning, as a first-line treatment if the cancer has spread, or if crizotinib has already been used.
Dosage form: capsules, hard
Active substance Dosage alectinib hydrochloride 161,33 mg -
It is used to treat several types of cancer in adults, including advanced colon or rectal cancer, metastatic breast cancer, advanced non-small cell lung cancer, advanced renal cancer, primary epithelial ovarian, fallopian tube, or peritoneal cancer, and persistent, recurrent, or metastatic cervical cancer.
Dosage form: solution for infusion, concentrate
Active substance Dosage bevacizumab 25 mg -
It is used to treat several types of cancer in adults, including advanced colon or rectal cancer, metastatic breast cancer, advanced non-small cell lung cancer, advanced renal cancer, primary epithelial ovarian, fallopian tube, or peritoneal cancer, and persistent, recurrent, or metastatic cervical cancer.
Dosage form: solution for infusion, concentrate
Active substance Dosage bevacizumab 25 mg -
It is used to prevent the body from rejecting a kidney, heart, or liver transplant in adults and children.
Dosage form: powder for preparation of oral suspension
Active substance Dosage mycophenolate mofetil 1 g -
It is used to prevent the body from rejecting a transplanted organ (kidney, heart, or liver) in adults and children.
Dosage form: capsules, hard
Active substance Dosage mycophenolate mofetil 250 mg -
It is used to prevent the body from rejecting a transplanted organ (kidney, heart, or liver) in adults and children.
Dosage form: tablets, film-coated
Active substance Dosage mycophenolate mofetil 500 mg -
It is used to prevent the body from rejecting a transplanted organ, specifically the kidney or the liver.
Dosage form: powder for concentrate for solution for infusion
Active substance Dosage mycophenolate mofetil 500 mg -
It is used to treat adults with a type of cancer called diffuse large B-cell lymphoma (DLBCL). It may be administered alone or in combination with other chemotherapy drugs, depending on whether the cancer has recurred or has not responded to previous treatments.
Dosage form: solution for infusion, concentrate
Active substance Dosage glofitamab 10 mg -
It is used to treat adults with a type of cancer called diffuse large B-cell lymphoma (DLBCL). It may be administered alone or in combination with other chemotherapy drugs, depending on whether the cancer has recurred or has not responded to previous treatments.
Dosage form: solution for infusion, concentrate
Active substance Dosage glofitamab 2,5 mg -
It is used to treat adult patients with a type of skin cancer called melanoma that has spread to other parts of the body or cannot be removed by surgery. It is used in combination with another medication called vemurafenib and only in patients with a specific mutation in the BRAF protein.
Dosage form: tablets, film-coated
Active substance Dosage cobimetinib 20 mg -
It is used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults and adolescents aged 12 years and older. This disease affects the optic nerves and the spinal cord due to a malfunction of the immune system.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage satralizumab 120 mg -
It is used to treat adults with a type of skin cancer called advanced basal cell carcinoma, whether it has spread to other parts of the body or to nearby areas, when it cannot be treated with surgery or radiation.
Dosage form: capsules, hard
Active substance Dosage vismodegib 150 mg -
It is used to treat Idiopathic Pulmonary Fibrosis (IPF) in adults. It helps reduce scarring and swelling in the lungs to make breathing easier.
Dosage form: tablets, film-coated
Active substance Dosage pirfenidone 267 mg -
It is used to treat Idiopathic Pulmonary Fibrosis (IPF) in adults. It helps to reduce scarring and swelling in the lungs to make breathing easier.
Dosage form: tablets, film-coated
Active substance Dosage pirfenidone 801 mg -
It is used to treat spinal muscular atrophy (SMA) in adults and children. It helps the body produce more SMN protein to improve muscle function.
Dosage form: powder for oral solution
Active substance Dosage risdiplam 0,75 mg -
It is used to treat spinal muscular atrophy (SMA) in both adults and children.
Dosage form: tablets, film-coated
Active substance Dosage risdiplam 5 mg -
It is used in adults to treat chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and lupus nephritis (LN), which is an inflammation of the kidney caused by lupus.
Dosage form: solution for infusion, concentrate
Active substance Dosage obinutuzumab 1000 mg -
It is used to treat patients of all ages with hemophilia A (congenital factor VIII deficiency), both in those who have developed factor VIII inhibitors and those who have not (in cases of severe or moderate disease with a severe bleeding phenotype). The medication helps to prevent or reduce bleeding episodes.
Dosage form: solution for injection
Active substance Dosage emicizumab 150 mg -
It is used to treat patients of all ages with hemophilia A (congenital factor VIII deficiency), both in those who have developed factor VIII inhibitors and those who have not (in cases of severe or moderate disease with a severe bleeding phenotype). It helps to prevent or reduce bleeding episodes.
Dosage form: solution for injection
Active substance Dosage emicizumab 30 mg -
It is used for the treatment of breast cancer (early or metastatic) and metastatic gastric cancer, provided that high levels of a protein called HER2 are present.
Dosage form: powder for concentrate for solution for infusion
Active substance Dosage trastuzumab 150 mg -
It is prescribed for the treatment of early or metastatic breast cancer in patients who have high levels of a protein called HER2.
Dosage form: solution for injection
Active substance Dosage trastuzumab 600 mg -
It is used to treat adult patients with breast cancer whose cancer cells have a high amount of the HER2 protein. It is prescribed whether the cancer has spread to other parts of the body or if it is administered after surgery.
Dosage form: powder for concentrate for solution for infusion
Active substance Dosage trastuzumab emtansine 20 mg -
It is used to treat adult patients with breast cancer whose cancer cells have a high amount of the HER2 protein. It can be administered if the cancer has spread to nearby areas or other parts of the body, or as therapy after surgery when the cancer has not spread.
Dosage form: powder for concentrate for solution for infusion
Active substance Dosage trastuzumab emtansine 20 mg -
It is used to treat adults with a type of blood cancer called follicular lymphoma (FL), specifically in patients who have already received at least two previous unsuccessful treatments or whose cancer has returned.
Dosage form: solution for infusion, concentrate
Active substance Dosage mosunetuzumab 1 mg -
It is used to treat adults with a type of blood cancer called follicular lymphoma (FL), specifically in patients who have already received at least two previous unsuccessful treatments or whose cancer has returned.
Dosage form: solution for infusion, concentrate
Active substance Dosage mosunetuzumab 30 mg -
It is used to treat Non-Hodgkin Lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis or microscopic polyangiitis, and pemphigus vulgaris.
Dosage form: solution for injection
Active substance Dosage rituximab 10 mg -
It is used for the treatment of non-Hodgkin lymphoma in adults.
Dosage form: solution for injection
Active substance Dosage rituximab 120 mg -
It is used to treat Non-Hodgkin Lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis or microscopic polyangiitis, and pemphigus vulgaris.
Dosage form: solution for injection
Active substance Dosage rituximab 50 mg -
It is used to treat anemia caused by chronic kidney disease in adults and children (from 3 months up to under 18 years of age) who are already receiving prior treatment with erythropoiesis-stimulating agents.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage methoxy-polyethylene glycol-epoetin beta 100 µg -
It is used to treat anemia caused by chronic kidney disease in adults and children (from 3 months up to less than 18 years old) who are already receiving prior treatment to stimulate red blood cell production.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage methoxy-polyethylene glycol-epoetin beta 120 µg -
It is used to treat anemia with symptoms (such as tiredness, weakness, or shortness of breath) caused by chronic kidney disease in adults and children between 3 months and under 18 years of age.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage methoxy-polyethylene glycol-epoetin beta 150 µg -
It is used to treat anemia caused by chronic kidney disease in adults and children (from 3 months up to under 18 years of age) who are already receiving prior treatment to stimulate red blood cell production.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage methoxy-polyethylene glycol-epoetin beta 200 µg -
It is used to treat anemia caused by chronic kidney disease in adults and children (from 3 months up to less than 18 years old) who are already receiving previous treatment to stimulate red blood cell production.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage methoxy-polyethylene glycol-epoetin beta 250 µg -
It is used to treat anemia caused by chronic kidney disease in adults and children (from 3 months up to less than 18 years old) who are already receiving prior treatment with erythropoiesis-stimulating agents.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage methoxy-polyethylene glycol-epoetin beta 30 µg -
It is used to treat anemia caused by chronic kidney disease in adults and children (from 3 months up to less than 18 years old) who are already receiving prior treatment to stimulate red blood cell production.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage methoxy-polyethylene glycol-epoetin beta 50 µg -
It is used to treat anemia caused by chronic kidney disease in adults and children (from 3 months up to less than 18 years of age) who are already receiving prior treatment with erythropoiesis-stimulating agents.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage methoxy-polyethylene glycol-epoetin beta 75 µg -
It is used to treat anemia caused by chronic kidney disease in patients with or without dialysis, to prevent anemia in premature infants, to treat anemia in adults with cancer receiving chemotherapy, and for individuals donating their own blood before surgery.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage epoetin beta 10 kilo UI -
It is used to treat anemia caused by chronic kidney disease in patients with or without dialysis, to prevent anemia in premature infants, to treat anemia in adults with cancer receiving chemotherapy, and for individuals who are going to donate their own blood before surgery.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage epoetin beta 30000 UI -
It is used to treat anemia caused by chronic kidney disease in patients with or without dialysis, to prevent anemia in premature infants, to treat anemia in adults with cancer receiving chemotherapy, and for individuals donating their own blood prior to surgery.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage epoetin beta 500 UI -
It is used to treat adults with relapsing forms of multiple sclerosis (RMS) and early primary progressive multiple sclerosis (PPMS).
Dosage form: solution for infusion, concentrate
Active substance Dosage ocrelizumab 30 mg -
It is used to treat adult patients with HER2-positive breast cancer, whether the cancer has spread to other parts of the body or is being administered before or after surgery.
Dosage form: solution for infusion, concentrate
Active substance Dosage pertuzumab 30,0 mg -
It is used to treat adult patients with HER2-positive breast cancer, either when the cancer has spread to other parts of the body or when treatment is needed before or after surgery.
Dosage form: solution for injection
Active substance Dosage pertuzumab 1200 mg trastuzumab 600 mg -
It is used to treat adult patients with HER2-positive breast cancer, either when the cancer has spread to other parts of the body or when treatment is required before or after surgery.
Dosage form: solution for injection
Active substance Dosage pertuzumab 600 mg trastuzumab 600 mg -
It is used to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults and adolescents aged 12 years and older who weigh 40 kg or more.
Dosage form: solution for injection and for infusion
Active substance Dosage crovalimab 340 mg -
It is used to treat previously untreated diffuse large B-cell lymphoma, or to treat this same type of cancer when it has recurred or has not improved after at least one previous treatment and the patient is not eligible for a stem cell transplant.
Dosage form: powder for concentrate for solution for infusion
Active substance Dosage polatuzumab vedotina 140 mg -
It is used to treat previously untreated diffuse large B-cell lymphoma, or to treat lymphoma that has recurred or has not improved after at least one previous treatment, and in cases where a stem cell transplant cannot be performed.
Dosage form: powder for concentrate for solution for infusion
Active substance Dosage polatuzumab vedotina 30 mg -
It is used to treat adults with active rheumatoid arthritis (moderate to severe or severe and progressive), adults with giant cell arteritis (inflammation of the arteries), and children or adolescents (12 years and older) with active systemic or polyarticular juvenile idiopathic arthritis.
Dosage form: solution for injection in pre-filled pen
Active substance Dosage tocilizumab 162 mg -
It is used to treat rheumatoid arthritis in adults, giant cell arteritis in adults, and systemic or polyarticular juvenile idiopathic arthritis in children and adolescents.
Dosage form: solution for injection in a pre-filled syringe
Active substance Dosage tocilizumab 162 mg -
It is used to treat active rheumatoid arthritis in adults, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA) in children aged 2 years and older, severe or potentially life-threatening cytokine release syndrome (CRS) in adults and children, and coronavirus disease 2019 (COVID-19) in adults requiring supplemental oxygen or mechanical ventilation.
Dosage form: solution for injection
Active substance Dosage tocilizumab 20 mg -
It is used to treat active rheumatoid arthritis in adults, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA) in children aged 2 years and older, severe or potentially life-threatening cytokine release syndrome (CRS) in adults and children, and coronavirus disease 2019 (COVID-19) in adults requiring oxygen or mechanical ventilation.
Dosage form: solution for injection
Active substance Dosage tocilizumab 20 mg